维布妥昔单抗-AVD与纳武利尤单抗-AVD一线治疗晚期霍奇金淋巴瘤的真实世界结局
这项多中心回顾性研究纳入17个美国中心2011年9月至2025年4月治疗的646例晚期霍奇金淋巴瘤患者,509例(78.8%)接受BV-AVD,137例(21.2%)接受N-AVD。N-AVD组中性粒细胞减少和感染发生率更高,BV-AVD组神经病变和剂量调整更常见;两组2年OS和PFS无显著差异,N-AVD的PFS数值上更优。
要点
- N-AVD组任何级别中性粒细胞减少77.2% vs BV-AVD组43.9%,感染31.9% vs 19.7%。
- BV-AVD组神经病变57.2% vs N-AVD组20.6%,剂量减少或省略35.8% vs 14.4%。
- 2年OS分别为BV-AVD 97%和N-AVD 100%(p=0.08),2年PFS 84% vs 88%(p=0.06)。
核心结论
- 真实世界中N-AVD与BV-AVD生存结局相当,N-AVD的PFS数值上更优,支持N-AVD作为晚期霍奇金淋巴瘤一线标准。
- N-AVD中性粒细胞减少和感染发生率更高,需密切监测并考虑生长因子预防。
研究设计与样本
- 多中心回顾性研究,纳入17个美国中心2011年9月至2025年4月治疗的646例晚期霍奇金淋巴瘤患者。
- 509例(78.8%)接受BV-AVD,137例(21.2%)接受N-AVD。
主要发现
- BV-AVD组剂量减少或省略更常见(35.8% vs 14.4%,p<0.0001)。
- N-AVD组任何级别中性粒细胞减少(77.2% vs 43.9%,p<0.0001)和≥3级中性粒细胞减少(58.1% vs 34.0%,p<0.0001)更高。
- N-AVD组感染发生率更高(31.9% vs 19.7%,p=0.004),但≥3级感染和发热性中性粒细胞减少两组相当。
- BV-AVD组神经病变显著更常见(57.2% vs 20.6%,p<0.0001)。
- 中位随访26.8个月,2年OS为97% vs 100%(p=0.08),2年PFS为84% vs 88%(p=0.06),倾向性评分匹配队列结果一致。
关键数值与推荐
- 治疗结束完全缓解率N-AVD组数值更高(86.2% vs 79.3%,p=0.11)。
临床怎么用
- N-AVD可作为晚期霍奇金淋巴瘤一线选择,但需警惕中性粒细胞减少和感染,考虑生长因子预防。
- BV-AVD需关注神经病变和剂量调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Brentuximab vedotin (BV)-doxorubicin, vinblastine and dacarbazine (AVD) and nivolumab (N)-AVD have transformed the frontline treatment of advanced-stage Hodgkin lymphoma (HL), yet real-world comparative data remain limited. In this multicentre retrospective study across 17 US centres, 646 patients treated between September 2011 and April 2025 were included; 509 (78.8%) received BV-AVD and 137 (21.2%) received N-AVD. Dose reductions or omissions were more common with BV-AVD (35.8% vs. 14.4%, p < 0.0001). N-AVD was associated with higher rates of neutropenia (any grade 77.2% vs. 43.9%, p < 0.0001; grade ≥3 58.1% vs. 34.0%, p < 0.0001) and infections (31.9% vs. 19.7%, p = 0.004), while grade ≥3 infections and febrile neutropenia were comparable. Neuropathy was significantly more frequent with BV-AVD (57.2% vs. 20.6%, p < 0.0001). End-of-therapy complete response rates were numerically higher with N-AVD (86.2% vs. 79.3%, p = 0.11). With a median follow-up of 26.8 months, 2-year overall survival (OS) was 97% for BV-AVD and 100% for N-AVD (p = 0.08) and 2-year progression-free survival (PFS) was 84% vs. 88% (p = 0.06). Survival outcomes were consistent in a 1:1 propensity score-matched cohort. These real-world data demonstrate comparable survival between regimens, with numerically improved PFS supporting N-AVD as a frontline standard for advanced-stage HL; however, higher rates of neutropenia and infections warrant careful monitoring and consideration of growth factor prophylaxis.
引用
- Chohan KL, Feng L, Cochran H, et al. Real-world outcomes of nivolumab-AVD and brentuximab vedotin-AVD in paediatric and adult advanced-stage Hodgkin lymphoma. Br J Haematol. 2026. PMID: 42802099. doi:10.1111/bjh.70854
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。